Display options
Cite
Barrangou-Poueys-Darlas M, Guerlais M, Laforgue EJ, et al. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. Drug Metab Rev. 2021;53(1):30-44doi: 10.1080/03602532.2020.1859528.
Barrangou-Poueys-Darlas, M., Guerlais, M., Laforgue, E. J., Bellouard, R., Istvan, M., Chauvin, P., Guillet, J. Y., Jolliet, P., Gregoire, M., & Victorri-Vigneau, C. (2021). CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. Drug metabolism reviews, 53(1), 30-44. https://doi.org/10.1080/03602532.2020.1859528
Barrangou-Poueys-Darlas, Malcolm, et al. "CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation." Drug metabolism reviews vol. 53,1 (2021): 30-44. doi: https://doi.org/10.1080/03602532.2020.1859528
Barrangou-Poueys-Darlas M, Guerlais M, Laforgue EJ, Bellouard R, Istvan M, Chauvin P, Guillet JY, Jolliet P, Gregoire M, Victorri-Vigneau C. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. Drug Metab Rev. 2021 Feb;53(1):30-44. doi: 10.1080/03602532.2020.1859528. Epub 2021 Jan 04. PMID: 33325257.
Copy Download .nbib Format: NLM
Share it on

Drug Metab Rev. 2021 Feb;53(1):30-44. doi: 10.1080/03602532.2020.1859528. Epub 2021 Jan 04.

CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation.

Drug metabolism reviews

Malcolm Barrangou-Poueys-Darlas, Marylène Guerlais, Edouard-Jules Laforgue, Ronan Bellouard, Marion Istvan, Pascale Chauvin, Jean-Yves Guillet, Pascale Jolliet, Matthieu Gregoire, Caroline Victorri-Vigneau

Affiliations

  1. Clinical Pharmacology Department, University Hospital Centre Nantes, Nantes, France.
  2. Addictology and Psychiatry Department, University Hospital Centre Nantes, Nantes, France.
  3. INSERM UMR 1246 SPHERE (methodS in Patients-centered outcomes and HEalth Research), Nantes and Tours Universities, Nantes, France.
  4. Addictology Regional Network (URAA), Structure Régionale d'Appui et d'Expertise Addictologie des Pays de la Loire, Nantes, France.
  5. INSERM UMR 1235 The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes, France.

PMID: 33325257 DOI: 10.1080/03602532.2020.1859528

Abstract

Smoking cessation is underestimated in terms of drug interactions. Abrupt smoking cessation is common in cases of emergency hospitalization and restrictions of movement. Tobacco is a known cytochrome P450 1A2 (CYP1A2) inducer, its consumption and withdrawal can lead to major pharmacokinetic drug interactions. Nevertheless, references do exist, but may have different results between them. The objective of our work was to establish the broadest and most consensual list as possible of CYP1A2 substrates treatments and propose a pharmacological approach. We searched the widest possible list of CYP1A2 substrates based on various international references. We compared the references and defined probability and reliability scores of our results to sort the substances based on the scores. For the 245 substances identified as CYP1A2 substrates, we focused on the 63 CYP1A2 substrates with both probability and reliability scores >50%. Our work establishes adaptive pharmacological approaches for the management of patients initiating smoking cessation which must be integrated into the management of smoking cessation. Pharmacologists can now adopt adaptive pharmacological approaches to complement patient-specific clinical information about smoking cessation by considering pharmacokinetic risk. This work establishes an unprecedented list. It should guide in the care of patients initiating smoking cessation to prevent pharmacokinetic drug interactions.

Keywords: Cytochrome P450; addiction medicine; drug interactions; pharmacokinetics; smoking cessation; tobacco

Publication Types